Rxivist logo

Recapitulation and reversal of schizophrenia-related phenotypes in Setd1a-deficient mice

By Jun Mukai, Enrico Cannavò, Gregg W Crabtree, Ziyi Sun, Anastasia Diamantopoulou, Pratibha Thakur, Chia-Yuan Chang, Yifei Cai, Stavros Lomvardas, Atsushi Takata, Bin Xu, Joseph A Gogos

Posted 26 Jan 2019
bioRxiv DOI: 10.1101/529701 (published DOI: 10.1016/j.neuron.2019.09.014)

SETD1A , a lysine-methyltransferase, is a key schizophrenia susceptibility gene. Mice carrying a heterozygous loss-of-function mutation of the orthologous gene exhibit alterations in axonal branching and cortical synaptic dynamics, accompanied by working memory deficits. We show that Setd1a binds both promoters and enhancers with a striking overlap between Setd1a and Mef2 on enhancers. Setd1a targets are highly expressed in pyramidal neurons and display a complex pattern of transcriptional up- and down-regulations shaped by presumed opposing functions of Setd1a on promoters and Mef2-bound enhancers. Notably, evolutionary conserved Setd1a targets are associated with neuropsychiatric genetic risk burden. Reinstating Setd1a expression in adulthood rescues cognitive deficits. Finally, we identify LSD1 as a major counteracting demethylase for Setd1a, and show that its pharmacological antagonism results in a full rescue of the behavioral and morphological deficits in Setd1a -deficient mice. Our findings advance understanding of how SETD1A mutations predispose to SCZ and point to novel therapeutic interventions.

Download data

  • Downloaded 1,772 times
  • Download rankings, all-time:
    • Site-wide: 7,814
    • In neuroscience: 835
  • Year to date:
    • Site-wide: 10,962
  • Since beginning of last month:
    • Site-wide: 34,722

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)